医学
白细胞介素17
安慰剂
炎症
银屑病性关节炎
银屑病
银屑病面积及严重程度指数
关节炎
类风湿性关节炎
免疫学
临床试验
内科学
免疫系统
细胞因子
痹症科
白细胞介素
药代动力学
胃肠病学
病理
替代医学
作者
Sophie Glatt,Dominique Baeten,TERRY S. BAKER,Meryn Griffiths,Lucian Ionescu,Alastair D. G. Lawson,Ash Maroof,Ruth Oliver,Serghei Popa,Foteini Strimenopoulou,Pavan Vajjah,Mark I L Watling,Nataliya G. Yeremenko,Pierre Miossec,Stevan Shaw
标识
DOI:10.1136/annrheumdis-2017-212127
摘要
OBJECTIVE: Interleukin (IL)-17A has emerged as pivotal in driving tissue pathology in immune-mediated inflammatory diseases. The role of IL-17F, sharing 50% sequence homology and overlapping biological function, remains less clear. We hypothesised that IL-17F, together with IL-17A, contributes to chronic tissue inflammation, and that dual neutralisation may lead to more profound suppression of inflammation than inhibition of IL-17A alone. METHODS: Preclinical experiments assessed the role of IL-17A and IL-17F in tissue inflammation using disease-relevant human cells. A placebo-controlled proof-of-concept (PoC) clinical trial randomised patients with psoriatic arthritis (PsA) to bimekizumab (n=39) or placebo (n=14). Safety, pharmacokinetics and clinical efficacy of multiple doses (weeks 0, 3, 6 (240 mg/160 mg/160 mg; 80 mg/40 mg/40 mg; 160 mg/80 mg/80 mg and 560 mg/320 mg/320 mg)) of bimekizumab, a humanised monoclonal IgG1 antibody neutralising both IL-17A and IL-17F, were investigated. RESULTS: cytokine responses and neutrophil chemotaxis than inhibition of IL-17A or IL-17F alone. The PoC trial met both prespecified efficacy success criteria and showed rapid, profound responses in both joint and skin (pooled top three doses vs placebo at week 8: American College of Rheumatology 20% response criteria 80.0% vs 16.7% (posterior probability >99%); Psoriasis Area and Severity Index 100% response criteria 86.7% vs 0%), sustained to week 20, without unexpected safety signals. CONCLUSIONS: These data support IL-17F as a key driver of human chronic tissue inflammation and the rationale for dual neutralisation of IL-17A and IL-17F in PsA and related conditions. TRIAL REGISTRATION NUMBER: NCT02141763; Results.
科研通智能强力驱动
Strongly Powered by AbleSci AI